Please login to the form below

Not currently logged in
Email:
Password:

UCB's Steve Arnold joins ABPI board

Will work to support life sciences in the UK

Steve Arnold joins UCB from GileadThe Association for the British Pharmaceutical Industry (ABPI has appointed UCB's Steve Arnold to its board of management.

Arnold joined UCB in May this year as managing director of the British and Irish Isles folliwng a spell in Canada working for Gilead Sciences.

He will serve as board member of the ABPPI – the UK's trade body for the pharma industry – up to 2014.

“As a leading UK pharma investor, UCB believes that harnessing this scientific innovation and increasing our R&D focus is key to improving the UK's future prosperity and as a member of the ABPI's board of management I will be working to ensure that life sciences remain vibrant in the UK,” said Arnold.

“This is particularly important at such a challenging time for our industry when we are looking for the Government to provide the right fiscal, R&D and commercial environment for our industry to thrive.”

31st July 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...

Infographics